Could a higher stem cell dose beat back lymphoma?
NCT ID NCT02570542
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether giving more stem cells during an autologous transplant helps people with relapsed or refractory diffuse large B-cell lymphoma recover better and stay cancer-free longer. About 59 adults who have already tried one chemotherapy will get high-dose chemo (BEAM) followed by a stem cell infusion. Researchers will compare different stem cell doses to see which leads to better immune recovery and longer time without the cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
stem cells (CD34+ cells) collected after plerixafor mobilization, followed by BEAM chemotherapy
What this could lead to
If successful, this could help doctors choose the best stem cell dose to improve recovery and delay lymphoma progression after transplant.
What could go wrong
This is a small, early-phase study with only 59 participants, so results may not apply to all patients. The transplant itself carries risks like infection and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University
New York, New York, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up Only)
Basking Ridge, New Jersey, United States
-
Memorial Sloan Kettering Bergen (Consent and Follow Up Only)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack (Consent and Follow-up Only)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (Consent and Follow up Only)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Consent and Follow up Only)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
-
Northwell Health (Data collection only)
Manhasset, New York, 11030, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
Texas Transplant Institute
San Antonio, Texas, 78229, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198-7680, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States